Glucocorticoid therapy

Glucocorticoid therapy in endocrinology encompasses the pharmacological interventions used to replace, modulate or temporarily enhance the biological effects of cortisol in patients with primary, secondary or tertiary adrenal insufficiency, in cases of iatrogenic suppression of the hypothalamic-pituitary-adrenal axis and in clinical situations in which glucocorticoid requirements increase acutely. The physiological cornerstone is the use of agents capable of reproducing the circadian rhythm of cortisol as closely as possible, while avoiding both chronic exposure to excessive doses and periods of insufficient coverage that expose patients to fatigue, haemodynamic instability, reduced tolerance to stress and, in extreme cases, adrenal crisis.

The objective of treatment is not merely to prescribe “a steroid”, but to restore a dynamic endocrine balance in which the physiology of the axis, the relative potency of the different agents, their half-life, absorption profile, dose distribution over 24 hours, the clinical context in which they are used and the patient’s ability to adjust treatment correctly during stressful events all play a role. The principles described on this page therefore provide the common framework guiding clinical practice, from chronic replacement therapy to perioperative management, from prevention of iatrogenic harm to interpretation of symptoms arising during treatment reduction, withdrawal or adjustment.

Glucocorticoid therapy is based on an essential physiological principle: in a healthy individual, cortisol is not secreted continuously at a constant rate, but according to circadian and ultradian rhythms, with levels rising during the early morning, progressively declining throughout the day and remaining low during the night. This temporal profile is as important as the total amount secreted, because many tissues respond not only to cumulative exposure but also to the time at which exposure occurs. Replacement therapy must therefore attempt to reproduce a plausible biological signal, while recognising that no conventional formulation can perfectly imitate the complexity of physiological secretion.

In established adrenal insufficiency, the primary objective is to prevent cortisol deficiency both at rest and during stress. This means controlling symptoms such as fatigue, weight loss, nausea, hypotension, reduced physical performance and susceptibility to infection, while also preventing the patient from remaining at risk of adrenal crisis during fever, trauma, surgery or intercurrent illness. Effective therapy, however, is not treatment that “eliminates every symptom” at the cost of chronic excess, but treatment that restores an acceptable functional state with the lowest necessary exposure. The central endocrine problem is that the margin between adequate replacement and iatrogenic overexposure is relatively narrow.

In patients with primary adrenal insufficiency, glucocorticoid replacement forms part of a broader clinical picture in which cortisol deficiency often coexists with mineralocorticoid and, to some extent, androgen deficiency. In secondary or tertiary adrenal insufficiency, by contrast, the deficit predominantly involves cortisol and is more frequently accompanied by other pituitary or hypothalamic deficiencies, with important implications for monitoring and clinical interpretation. In both conditions, however, the therapeutic rationale remains the same: to provide enough glucocorticoid to support metabolism, vascular tone, immune responses and adaptation to stress without reproducing the systemic burden of anti-inflammatory or immunosuppressive therapy.

Alongside chronic replacement, there is a second major endocrine objective involving the management of iatrogenic suppression of the axis caused by exogenous glucocorticoids. In these patients, treatment is not intended to replace a permanently destroyed or under-stimulated gland, but to provide coverage during a recovery phase in which the hypothalamic-pituitary-adrenal axis has not yet regained full autonomy. This makes glucocorticoid therapy a precision discipline: the same class of drugs is used for different objectives according to the clinical context, with a constant need to translate physiology, pharmacology and clinical risk into measurable and safe decisions.

The agents used in endocrine glucocorticoid therapy are not interchangeable on a purely “quantitative” basis because they differ in potency, half-life, receptor affinity, residual mineralocorticoid activity and their ability to generate peaks or plateaux of exposure. Hydrocortisone, which is chemically identical to cortisol, remains the most physiological reference treatment for replacement therapy because it has a relatively short duration of action and allows doses to be distributed in a way that more closely mimics the natural rhythm. This short half-life, however, makes it difficult to achieve continuous coverage without alternating periods of under-replacement with episodes of post-dose overexposure.

Cortisone acetate is another long-established option, but it requires hepatic conversion to hydrocortisone and may be less predictable in certain clinical conditions. Prednisone and prednisolone, because of their greater potency and longer duration of action, allow simpler administration in some patients, often once daily, but this convenience comes at the cost of a less physiological profile and the risk, when dosing is not precise, of maintaining excessive glucocorticoid exposure for many hours. Because of its extremely high potency and long duration of action, dexamethasone is generally not the preferred option for chronic replacement in adults with adrenal insufficiency, as it increases the likelihood of overdosing and makes it more difficult to adjust treatment according to actual requirements.

A crucial point is that pharmacokinetics does not merely describe “how much drug enters the circulation”, but determines the temporal quality of the endocrine signal. Conventional hydrocortisone formulations typically produce a relatively rapid peak followed by an equally marked decline; consequently, the patient may experience temporary well-being after taking a dose, followed by the recurrence of fatigue, weakness or impaired concentration before the next dose. This explains the growing interest in modified-release or dual-release formulations, developed to more closely approximate the physiological cortisol profile and reduce the metabolic and immunological consequences of an unnatural distribution of exposure.

The pharmacology of replacement glucocorticoids is therefore not a technical detail but the foundation of clinical practice. Two patients receiving an “equivalent dose” may in reality be exposed to very different endocrine signals depending on the agent, the number of daily administrations, the timing of each dose and individual characteristics of absorption and metabolism. Drug selection must therefore always be regarded as an integral part of the therapeutic strategy rather than a simple prescribing preference.

Initiating glucocorticoid therapy requires three objectives to be reconciled: correcting the hormonal deficiency, respecting circadian physiology as closely as possible and limiting cumulative exposure to excess steroid. In adults with stable adrenal insufficiency, guidelines generally recommend a total daily hydrocortisone dose of 15-25 mg, divided into two or three administrations, with the largest dose taken on waking and progressively smaller doses later in the day. This regimen reflects the need to provide the greatest support during the early hours of the day, when physiological cortisol levels are highest, and to avoid evening and nocturnal exposure that may disrupt sleep, metabolism and the blood pressure profile.

The initial dose, however, is only a starting point. Unlike other endocrine axes, there is no single simple, stable and universally reliable biomarker that permits glucocorticoid therapy to be titrated in the same way that, for example, TSH is used in thyroid replacement therapy. Dose adjustment is therefore based primarily on the integration of clinical data: energy levels, weight, blood pressure, exercise tolerance, pre-dose symptoms, the development of insomnia or agitation, metabolic trends and, in primary adrenal insufficiency, coordination with mineralocorticoid therapy. Adjustment is therefore less “algorithmic” and more closely linked to an endocrine interpretation of the clinical context.

In patients with secondary or tertiary adrenal insufficiency, treatment planning must also take into account the presence of other pituitary deficiencies. In particular, initiating thyroid hormone therapy in a patient with unrecognised or untreated adrenal insufficiency can increase cortisol metabolism and precipitate clinical decompensation. Similarly, changes in oestrogen therapy, somatic growth or body size, liver function or inflammatory status may modify the apparent glucocorticoid requirement and necessitate reassessment of dose distribution.

A second aspect of treatment planning concerns the reduction of glucocorticoid therapy in patients exposed to supraphysiological doses for non-endocrine diseases. In this setting, the problem is not to establish a definitive replacement dose, but to guide the patient from an anti-inflammatory or immunosuppressive regimen towards the physiological range, recognising that the initial phase of dose reduction may be relatively rapid, whereas the final phase requires greater caution. It is precisely when doses approach physiological requirements that residual axis suppression becomes more evident and it becomes more difficult to distinguish adrenal insufficiency, glucocorticoid withdrawal syndrome and reactivation of the underlying disease.

Monitoring glucocorticoid therapy must answer a central question: is the patient receiving enough hormone to live safely, but not so much as to cause chronic harm? In clinical practice, this monitoring is primarily clinical. Signs of under-replacement include persistent fatigue, weight loss, nausea, hypotension, worsening exercise tolerance, a frequent need to take the next dose early and marked deterioration during intercurrent illness. Signs of excess include weight gain, insomnia, agitation, skin fragility, worsening glycaemic control, increased blood pressure and, over time, the development or progression of osteopenia, sarcopenia and an iatrogenic Cushingoid phenotype.

Biochemical tests may be helpful, but they rarely replace clinical judgement. Serum cortisol measurement after oral hydrocortisone is difficult to interpret without precise standardisation of sampling time and provides only a snapshot of a highly dynamic profile. Similarly, ACTH and other markers do not allow precise titration of daily replacement therapy in most cases. In selected subgroups, particularly in specialist or research settings, salivary or serum profiles may be used to better characterise exposure, but in routine practice the core of monitoring remains the systematic assessment of the relationship between dose, timing and symptoms.

In patients with primary adrenal insufficiency, part of the monitoring process also involves appropriate integration with mineralocorticoid therapy, because symptoms such as orthostatic hypotension, salt craving and fatigue are not always caused solely by glucocorticoid deficiency. In secondary or tertiary adrenal insufficiency, by contrast, assessment must take into account other endocrine replacement therapies, pituitary comorbidities and the fact that electrolyte balance may remain relatively better preserved than in primary disease.

A specific aspect of monitoring is the assessment of axis recovery in patients with iatrogenic suppression. In these cases, morning cortisol is the most useful initial test once the patient has reached physiological or near-physiological doses and the objective is complete discontinuation. Even in this setting, however, the biochemical result must be interpreted within the patient’s clinical trajectory: symptoms, the type of glucocorticoid used, the duration of previous treatment and the time elapsed since dose reduction or withdrawal substantially influence interpretation of the result.

Glucocorticoid requirements are not fixed. They change with fever, infections, trauma, surgery, vomiting, diarrhoea, intense physical exercise, changes in body weight, drug interactions and the overall inflammatory state. This makes glucocorticoid therapy different from many other forms of endocrine replacement: a dose that is “correct” under baseline conditions may become insufficient within hours if the patient experiences significant systemic stress. The concept of stress dosing is therefore an integral part of therapy rather than an additional measure reserved only for emergencies.

During fever, acute infection or another non-severe systemic illness, the patient must be instructed to increase the dose temporarily according to precise rules agreed with the treating centre. If vomiting, significant diarrhoea, inability to take oral medication or rapid clinical deterioration occurs, the problem is no longer simply to increase the oral dose, but to ensure prompt parenteral administration of hydrocortisone and urgent medical support. This transition is a decisive determinant of prognosis, because many adrenal crises are not caused by incorrect baseline therapy, but by failure to adjust the dose during sudden stress.

Drug interactions primarily affect metabolism and systemic exposure. Enzyme inducers may increase glucocorticoid clearance and render previously effective doses inadequate; conversely, metabolic inhibitors may increase exposure and promote toxicity or axis suppression. The route of administration also matters: inhaled, intranasal, topical, intra-articular or parenteral glucocorticoids, when used at high doses, for prolonged periods or in combination, can make a clinically significant contribution to suppression of the hypothalamic-pituitary-adrenal axis, even though the patient may not perceive them as “true systemic steroid therapy”.

There is also considerable variability during recovery after withdrawal of chronic supraphysiological therapy. The time required for the axis to recover is highly individual and depends on treatment duration, dose, drug potency, pharmacokinetic profile and personal susceptibility. Consequently, two patients with apparently similar exposure may follow very different trajectories. The clinician’s task is therefore not to apply the same rigid regimen to every patient, but to recognise when variability is physiologically plausible and when it indicates suboptimal management or an inadequately controlled risk of adrenal insufficiency.

Glucocorticoid therapy has specific characteristics in special populations because the balance between benefit and risk becomes narrower and the consequences of dosing errors become more significant. During pregnancy, for example, continuity of replacement therapy is essential to protect the mother from decompensation and adrenal crisis. Hydrocortisone remains the most physiological choice in most cases and, particularly during the third trimester, a dose increase may be required when clinical signs indicate increased requirements. Labour, vaginal delivery and caesarean section also require specific coverage regimens because they represent major endocrine stressors.

In children and neonates, prompt and precise treatment is essential. Dosing is calculated according to body surface area and must take into account growth, development, pubertal maturation and, in patients with congenital adrenal hyperplasia, the need to balance physiological replacement against control of androgen excess. In paediatric patients, small differences in dose may produce clinically significant effects on linear growth, body weight, blood pressure and bone maturation, requiring even closer control of the relationship between efficacy and iatrogenic harm.

In older adults, replacement therapy must take account of frailty, cardiovascular comorbidities, reduced functional reserve, polypharmacy and greater susceptibility to the metabolic and skeletal effects of chronic overdosing. In these patients, it is not appropriate to pursue an apparent pharmacologically induced “vitality” through excessive doses; instead, the objective is to maintain sufficient, stable and safe coverage while limiting insomnia, sarcopenia, increased blood pressure, deterioration of glucose metabolism and fracture risk.

A distinct setting is that of patients with multiple pituitary hormone deficiencies or recent withdrawal of glucocorticoids used for non-endocrine diseases. In these cases, glucocorticoid therapy cannot be considered in isolation because it interacts with thyroid, gonadal and growth hormone replacement and with the dynamics of axis recovery. In these settings, precision medicine does not consist of sophisticated technologies, but of the ability to interpret clinical signs within a broad and coherent endocrine framework.

Conventional replacement therapy with hydrocortisone administered two or three times daily remains the standard for most patients, but recent years have seen growing interest in strategies capable of more closely reproducing cortisol physiology. Modified-release or dual-release formulations represent the most developed approach in this direction: rather than simply improving convenience, they aim to produce a less artificial exposure profile, with potential benefits for body weight, glucose metabolism, innate immunity and quality of life in selected patients.

Another advanced strategy involves the selective use of prednisolone for replacement, particularly when adherence to multiple daily doses is problematic or a simpler regimen is required. However, this simplification is appropriate only when accompanied by accurate titration because the greater potency of prednisolone makes it easy to exceed physiological requirements. The relevant question is therefore not “which agent is best in absolute terms”, but which exposure profile is most appropriate for the individual patient at a particular stage of their clinical course.

A third crucial area is the tapering of glucocorticoids after chronic supraphysiological use. The most recent guidelines emphasise that dose reduction may proceed more rapidly while the patient remains within a clearly non-physiological range, but must become slower as the physiological equivalent is approached. During this phase, the clinician must distinguish between three conditions that frequently overlap: persistent suppression of the axis, glucocorticoid withdrawal syndrome and exacerbation of the disease for which steroids were originally prescribed. Confusing these scenarios can easily lead to errors, such as unnecessarily prolonging treatment that is no longer required or discontinuing it too early and exposing the patient to adrenal insufficiency.

In summary, advanced strategies are not shortcuts, but controlled extensions of the endocrine method. Circadian timing, simplification of the regimen, individualisation of the agent and tapering of a suppressed axis are useful tools only when there is a clearly defined objective, appropriate monitoring and an explicit awareness of the biological cost of chronic glucocorticoid excess.

The safety of glucocorticoid therapy depends on a delicate balance. Chronic overtreatment gradually exposes the patient to a phenotype of iatrogenic hypercortisolism that may initially be subtle but, over time, promotes weight gain, hyperglycaemia, hypertension, dyslipidaemia, loss of muscle mass, osteopenia, skin fragility, sleep disturbances and worsening cardiovascular risk. This harm does not necessarily require markedly high doses: even mild overexposure sustained for years may produce clinically significant consequences, particularly in older patients or those already vulnerable from a metabolic or skeletal perspective.

Undertreatment is less conspicuous but no less dangerous. An insufficient dose leaves the patient with reduced tolerance to stress, fatigue, weight loss, haemodynamic instability and an increased risk of decompensation during intercurrent illness. If this situation is incorrectly interpreted as a “need for time to adapt” or as a non-specific condition, progression towards adrenal crisis may be underestimated. Adrenal crisis is the most serious consequence of inadequate glucocorticoid therapy or failure to adjust treatment during stress and is a time-critical emergency requiring immediate parenteral hydrocortisone and haemodynamic support.

In patients with an axis suppressed by exogenous glucocorticoids, safe management also requires recognition that symptoms during tapering do not always indicate overt adrenal insufficiency. Withdrawal syndrome may present with myalgia, arthralgia, weakness, nausea, sleep disturbances and mood changes, partially overlapping with glucocorticoid deficiency. The greatest clinical risk arises when this overlap leads to impulsive decisions, such as abrupt dose increases or sudden discontinuation, without a coherent interpretation of the dose reached and the duration of previous exposure.

Prevention of iatrogenic harm is therefore based on four elements: selection of the appropriate agent, use of the lowest effective dose, rigorous education regarding stress dosing and availability of a clear emergency plan. Glucocorticoid therapy becomes safer when it is regarded not as a static prescription, but as a continuous endocrine intervention that must remain stable under baseline conditions and flexible during stress.

Glucocorticoid replacement therapy is effective only when the patient understands that it is not a “symptomatic” drug, but a life-sustaining form of hormone replacement in many clinical conditions. Adherence involves more than simply remembering each dose: it also requires compliance with timing, daily dose distribution, adjustment during stressful events and management of situations in which oral administration becomes impossible. A substantial proportion of complications arise not from the initial selection of the agent, but from interruption of therapeutic continuity at critical moments.

Therapeutic education must cover several essential aspects: recognising symptoms of excessive or insufficient treatment, knowing when to increase the dose temporarily, understanding when vomiting or diarrhoea requires a change in the route of administration, having access to emergency parenteral hydrocortisone and carrying medical identification indicating the risk of adrenal crisis. This practical knowledge is not merely an educational addition, but an integral component of treatment itself because it transforms the patient from a passive recipient into the first line of prevention against adrenal crisis.

Quality of life also requires a methodical assessment. Persistent fatigue, reduced performance, cognitive symptoms or impaired well-being should not automatically lead to an increase in the dose because the same symptoms may be caused by inadequate sleep, anaemia, depression, autoimmune comorbidities, associated thyroid dysfunction, physical deconditioning or the effects of other treatments. Without this assessment, there is a risk of using the glucocorticoid dose as the explanation for every symptom, resulting in progressive overdosing.

Finally, good adherence is also built on simple and repeatable rules. The patient must know which warning signs require early contact with the treating clinician, how to manage treatment before invasive procedures or surgery, and under which circumstances omission or delay of a dose represents a genuine danger. When this close therapeutic partnership functions effectively, glucocorticoid therapy becomes more stable, safer and less vulnerable to fluctuations that might otherwise be incorrectly attributed to an intrinsic lack of treatment efficacy.